ストックスクリーナーアプリを入手
41.49
4.93%
1.95
アフターアワーズ：
41.49
前日終値:
$39.54
開ける：
$39.01
24時間の取引高:
1.99M
Relative Volume:
2.92
時価総額：
$2.47B
収益：
$45.48M
当期純損益:
$169.95M
株価収益率:
-15.48
EPS:
-2.68
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
+1.00%
1か月 パフォーマンス:
+2.07%
6か月 パフォーマンス:
+32.01%
1年 パフォーマンス:
+99.95%
1日の値動き範囲:
$38.91
$41.68
1週間の範囲:
$38.61
$41.97
52週間の値動き範囲:
$20.88
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
41.49 | 2.47B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Barclays PLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
HighTower Advisors LLC Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Wellington Management Group LLP Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - Corsicana Daily Sun
Protagonist Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Teachers Retirement System of The State of Kentucky Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
(PTGX) Trading Signals - Stock Traders Daily
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical trials - Investing.com
State Street Corp Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
XTX Topco Ltd Takes $666,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Clear Street sets $63 target on Protagonist Therapeutics By Investing.com - Investing.com Canada
BNP Paribas Financial Markets Purchases 16,597 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
BTIG maintains shares target on Protagonist Therapeutics, cites trial By Investing.com - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Fmr LLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist's Rusfertide Shows Breakthrough Results in Phase 2 PV Study: 54% Hit Key Treatment Goals - StockTitan
The Goldman Sachs Group Begins Coverage on Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Weiss Asset Management LP Makes New $2.81 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Point72 Asset Management L.P. Sells 694,862 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by BMO Capital Markets - MarketBeat
BMO Capital Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN
Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 39,850 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
(PTGX) Technical Data - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by RTW Investments LP - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by HighVista Strategies LLC - MarketBeat
Walleye Capital LLC Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Public Sector Pension Investment Board Invests $5.62 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Thrivent Financial for Lutherans Invests $2.08 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Intech Investment Management LLC Invests $861,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics chief development officer sells $5.6 million in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics CEO sells $4.68 million in stock By Investing.com - Investing.com Nigeria
Protagonist Therapeutics' chief medical officer sells $1.41 million in stock By Investing.com - Investing.com South Africa
Swedbank AB Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics CEO sells $4.68 million in stock - Investing.com India
Protagonist Therapeutics' chief medical officer sells $1.41 million in stock - Investing.com India
Protagonist Therapeutics chief development officer sells $5.6 million in stock - Investing.com
Advantage Alpha Capital Partners LP Acquires Shares of 11,336 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Nigeria
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Objective long/short (PTGX) Report - Stock Traders Daily
Algert Global LLC Sells 36,400 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Victory Capital Management Inc. Has $5.89 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics selects IL-17 antagonist as development candidate - BioWorld Online
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 - AccessWire
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Option Exercise |
8.04 |
5,529 |
44,453 |
51,973 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 27 '24 |
Sale |
44.70 |
26,000 |
1,162,280 |
46,444 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Sale |
45.60 |
5,529 |
252,122 |
46,444 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Option Exercise |
7.75 |
175,000 |
1,356,000 |
359,611 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Option Exercise |
12.17 |
30,450 |
370,576 |
286,174 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Sale |
46.04 |
103,437 |
4,762,239 |
256,174 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Sale |
45.50 |
19,191 |
873,190 |
266,983 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Option Exercise |
21.58 |
1,727 |
37,269 |
429,935 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Sale |
46.96 |
78,520 |
3,687,299 |
435,208 |
| PATEL DINESH V PH D | President and CEO |
Nov 26 '24 |
Sale |
46.25 |
21,480 |
993,450 |
408,455 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):